← All trials
NCT04620239
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 11, 2021
- Primary completion
- Jun 10, 2022
- Completion date
- Jun 6, 2023
- First posted
- Nov 6, 2020
- Last posted
- Nov 24, 2020
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Steba Biotech S.A.Lead sponsor
- ICONCollaborator
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
- Medpace, Inc.Collaborator
- PrimeVigilance LTDCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.